Repeat Revascularization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Repeat revascularization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Repeat Revascularization Today - Breaking & Trending Today

Marizyme Announces Approval for DuraGraft® in India

Marizyme Announces Approval for DuraGraft® in India
Latest Approval Joins a Growing List of Countries for Commercial Sales in 2021
News provided by
Share this article
Share this article
JUPITER, Fla., Jan. 14, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB:MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, announced today that its flagship product DuraGraft
® is now registered and licensed for import into India through Marizyme s distribution partner Regency Lifesciences.
India represents the latest market approval for DuraGraft, a CE-marked product that protects vascular grafts against ischemic injury and is the only product approved for graft protection and preservation during bypass and other vascular surgeries. Currently, DuraGraft is approved in the EU and seven additional countries with more world-wide ....

United States , Ingrid Mezo , Abel Alexander , Maureen Mcenroe , Miriam Miller , Neil Campbell , Indian Health , Marizyme Inc , Regency Lifesciences , Artery Bypass Graft Surgeries , Myocardial Infarction , Repeat Revascularization , Major Adverse Cardiac Events , Leading Distributor , Healthcare Devices , Health Care Amp Hospitals , Small Cap , Medical Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் , ஏபெல் அலெக்சாண்டர் , மவ்ரீன் அம்கெந்ரொ , மிரியம் மில்லர் , நீல் கேம்ப்பெல் , இந்தியன் ஆரோக்கியம் , ரீஜென்சி ஆயுள் அறிவியல் , தமனி பைபாஸ் ஒட்டு அறுவை சிகிச்சைகள் ,

Marizyme Announces the Use of DuraGraft® as the Standar

11 gennaio 2021 | 11.34
LETTURA: 5 minuti
DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure
JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the company s flagship product, DuraGraft® as the standard-of-care for flushing and storage of the saphenous vein grafts from harvesting through grafting in Coronary Artery Bypass Grafting (CABG) patients. ....

Ingrid Mezo , Maximilian Emmert , Martin Grabwenw , Miriam Miller , Neilj Campbell , Exchange Commission , Contacts Tiberend Strategic Advisors Inc Investorsmaureen Mcenroe , Vascular Center , Vienna Heart Center North Floridsdorf , German Heart Center Berlin , Marizyme Inc , Coronary Artery Bypass Grafting , Heart Center North Floridsdorf , Assess Outcomes , Vascular Conduits , Cardiac Surgery Center , Associate Professor , Bernhard Winkler , Vienna Heart Center North , Cardiac Surgery , Chief Executive Officer , Duragraft When , Myocardial Infarction , Repeat Revascularization , Looking Statements This , Tiberend Strategic Advisors ,

Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in [...]

11 gennaio 2021 11:38
Fonte: Adnkronos
#salute-e-benessere
DuraGraft is a one-time intraoperative treatment used during vascular surgery to reduce the incidence of complications associated with graft failure
JUPITER, Fla., Jan. 11, 2021 /PRNewswire/ Marizyme, Inc. (OTCQB: MRZM), a global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, organ transplant, and other surgical indications, today announced as of August 2020 the Vienna Heart Center North Floridsdorf of Vienna, Austria was the first clinic worldwide to use the company s flagship product, DuraGraft® as the standard-of-care for flushing and storage of the saphenous vein grafts from harvesting through grafting in Coronary Artery Bypass Grafting (CABG) patients. ....

Ingrid Mezo , Maximilian Emmert , Martin Grabwenw , Miriam Miller , Neilj Campbell , Exchange Commission , Contacts Tiberend Strategic Advisors Inc Investorsmaureen Mcenroe , Vascular Center , Vienna Heart Center North Floridsdorf , German Heart Center Berlin , Marizyme Inc , Coronary Artery Bypass Grafting , Heart Center North Floridsdorf , Assess Outcomes , Vascular Conduits , Cardiac Surgery Center , Associate Professor , Bernhard Winkler , Vienna Heart Center North , Cardiac Surgery , Chief Executive Officer , Duragraft When , Myocardial Infarction , Repeat Revascularization , Looking Statements This , Tiberend Strategic Advisors ,

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During J.P. Morgan Week 2021

Registration: https://informaconnect.com/biotech-showcase/registration-options/
During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company s flagship product, DuraGraft
, an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase ....

Ingrid Mezo , Kostenloser Wertpapierhandel , Maureen Mcenroe , Miriam Miller , Neilj Campbell , Tiberend Strategic Advisors Inc , Exchange Commission , Prnewswire Marizyme Inc , Marizyme Inc , Chief Executive Officer , Biotech Showcase Digital , Biotech Showcase , Myocardial Infarction , Repeat Revascularization , Strategic Advisors , மவ்ரீன் அம்கெந்ரொ , மிரியம் மில்லர் , பரிமாற்றம் தரகு , தலைமை நிர்வாகி அதிகாரி , பயோடெக் காட்சி பெட்டி டிஜிட்டல் , பயோடெக் காட்சி பெட்டி ,

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During "J.P. Morgan Week 2021"

During BIO @ JPM and Biotech Showcase Digital, Dr. Campbell will host virtual one-on-one meetings with registered investors and pharmaceutical companies to discuss Marizyme s pipeline of therapies that address urgent needs related to higher mortality and costs in the acute care space. The company s flagship product, DuraGraft
®, an intra-operative vascular graft storage solution that inhibits endothelial damage, leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease-based therapeutic Krillase ....

Ingrid Mezo , Maureen Mcenroe , Miriam Miller , Neilj Campbell , Exchange Commission , Marizyme Inc , Chief Executive Officer , Biotech Showcase Digital , Biotech Showcase , Myocardial Infarction , Repeat Revascularization , மவ்ரீன் அம்கெந்ரொ , மிரியம் மில்லர் , பரிமாற்றம் தரகு , தலைமை நிர்வாகி அதிகாரி , பயோடெக் காட்சி பெட்டி டிஜிட்டல் , பயோடெக் காட்சி பெட்டி ,